innate immunity to candida albicans
Clicks: 229
ID: 236662
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
229 views
43 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #19 of 26 articles by views in clinical journal of the american society of nephrology : cjasn
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Candida albicans is not a pathogen in healthy individuals, but can cause severe systemic candidiasis in immunocompromised patients. C. albicans has various virulence factors and activates the innate immune system. Specifically, C. albicans induces proinflammatory cytokine production in various cell types via many receptors, such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs). This microorganism also promotes phagocytosis via CLRs on macrophages. In a previous study, we found that C. albicans induces the production of galectin-3, which is a known CLR that kills C. albicans. This review indicates that the use of mouthwash containing an antimicrobial peptide or protein might be a useful new oral care method for the prevention of oral candidiasis.
| Reference Key |
kiyoura2015japaneseinnate
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Yusuke Kiyoura;Riyoko Tamai |
| Journal | clinical journal of the american society of nephrology : cjasn |
| Year | 2015 |
| DOI |
10.1016/j.jdsr.2014.12.001
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.